Literature DB >> 8095023

Opioid receptor-mediated inhibition of evoked catecholamine release from cultured neurons of rat ventral mesencephalon and locus coeruleus.

E Ronken1, F L Van Muiswinkel, A H Mulder, A N Schoffelmeer.   

Abstract

The effects of selective opioid agonists on the evoked release of [3H]dopamine and [3H]noradrenaline were studied in cultured dopaminergic neurons of the ventral mesencephalon (containing the substantia nigra and ventral tegmental area) and in cultured neurons of the noradrenergic locus coeruleus, respectively. The cultures were prepared from embryonic day 15 rat brains. After 9 days in culture, the calcium-dependent release of [3H]dopamine from dopaminergic substantia nigra/ventral tegmental area neurons induced by 23 mM k+ appeared to be inhibited exclusively by activation of kappa-opioid receptors, as [3H]dopamine release was inhibited selectively by the kappa agonists U69,593 and dynorphin-(1-13) (EC50 8 and 5 nM, respectively), and this inhibitory effect was antagonized by the kappa-selective antagonist nor-binaltorphimine (Ki 0.07 nM). In contrast, cultured noradrenergic locus coeruleus neurons appeared to contain release-inhibitory mu-opioid receptors only, as evoked [3H]noradrenaline release was inhibited selectively by the mu agonist [D-Ala2, MePhe4, Gly-ol5]enkephalin (EC50 45 nM), a response that was antagonized by the preferential mu antagonist naloxone (Ki = 0.7 nM). The delta-opioid receptor agonist [D-Ser2(O-butyl), Leu5]enkephalyl-Thr6 did not affect catecholamine release. Dopamine release from cultured ventral mesencephalic neurons, induced by 100 microM N-Methyl-D-Aspartate (NMDA), also appeared to be subject to kappa receptor-mediated inhibition, whereas NMDA-induced noradrenaline release from cultured locus coeruleus neurons was under the inhibitor control of mu receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095023     DOI: 10.1016/0014-2999(93)90572-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Tau Protein Levels in ADHD.

Authors:  Keith Fluegge
Journal:  Indian J Clin Biochem       Date:  2018-04-19

Review 2.  Role of kappa-opioid receptors in stress and anxiety-related behavior.

Authors:  Ashlee Van't Veer; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

3.  Attentional function and inhibitory control in different substance use disorders.

Authors:  James M Bjork; Lori Keyser-Marcus; Jasmin Vassileva; Tatiana Ramey; David C Houghton; F Gerard Moeller
Journal:  Psychiatry Res       Date:  2022-05-01       Impact factor: 11.225

Review 4.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

5.  Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.

Authors:  Yuanzi Zhao; Anand A Joshi; Jane V Aldrich; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2021-09-15       Impact factor: 6.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.